At close: December 24 at 1:48:15 PM GMT+1
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
1,681.52
1,681.52
1,548.98
1,537.99
1,256.10
Cost of Revenue
-471.40
-471.40
-479.20
-517.33
-477.45
Gross Profit
2,152.92
2,152.92
2,028.18
2,055.31
1,733.55
Operating Expense
2,764.85
2,764.85
3,246.42
3,677.50
3,325.58
Operating Income
-611.93
-611.93
-1,218.24
-1,622.19
-1,592.03
Net Non Operating Interest Income Expense
-112.73
-112.73
-97.76
-90.44
-79.13
Pretax Income
-553.73
-553.73
-1,248.07
-1,701.76
-1,483.70
Tax Provision
-632.90
-632.90
-845.53
-833.48
-819.53
Net Income Common Stockholders
79.17
79.17
-402.54
-868.29
-664.16
Diluted NI Available to Com Stockholders
79.17
79.17
-402.54
-868.29
-664.16
Basic EPS
0.07
0.07
-0.36
-0.80
-0.61
Diluted EPS
0.07
0.07
-0.36
-0.80
-0.61
Basic Average Shares
1,086.49
1,130.99
1,118.17
1,085.36
1,088.79
Diluted Average Shares
1,086.49
1,130.99
1,118.17
1,085.36
1,088.79
Total Operating Income as Reported
-778.24
-778.24
-1,453.95
-1,945.99
-1,595.94
Total Expenses
2,293.45
2,293.45
2,767.22
3,160.18
2,848.13
Net Income from Continuing & Discontinued Operation
79.17
79.17
-402.54
-868.29
-664.16
Normalized Income
-1.95
-1.95
-430.08
-864.41
-783.07
Interest Income
78.00
--
--
0.22
0.19
Interest Expense
112.73
112.73
84.99
85.34
79.32
Net Interest Income
-112.73
-112.73
-97.76
-90.44
-79.13
EBIT
-441.01
-441.01
-1,163.08
-1,616.42
-1,404.38
EBITDA
72.53
72.53
-637.07
-879.66
-743.38
Reconciled Cost of Revenue
-471.40
-471.40
-479.20
-517.33
-477.45
Reconciled Depreciation
513.54
513.54
1.07
1.34
661.00
Net Income from Continuing Operation Net Minority Interest
79.17
79.17
-402.54
-868.29
-664.16
Total Unusual Items Excluding Goodwill
108.17
108.17
36.72
-5.28
165.15
Total Unusual Items
108.17
108.17
36.72
-5.28
165.15
Normalized EBITDA
-35.64
-35.64
-673.79
-874.38
-908.53
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
27.04
27.04
9.18
-1.40
46.24
12/31/2020 - 9/27/2011
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
MAAT.PA MaaT Pharma SA
7.94
+0.76%
ALMDP.PA Medesis Pharma S.A.
0.3150
+0.32%
ALINT.PA IntegraGen SA
0.5150
-2.83%
ALNFL.PA NFL Biosciences SA
1.7960
-0.33%
ALPHA.PA Pharnext S.C.A.
0.0002
0.00%
ALOPM.PA Oncodesign Precision Medicine Société anonyme
0.7600
-2.56%
ALSEN.PA Sensorion SA
0.6160
-0.32%
ALVET.PA TheraVet SA
0.1085
+2.36%
PHIL.MI Philogen S.p.A.
19.20
+0.52%
ALQGC.PA Quantum Genomics Société Anonyme
0.0721
0.00%